Bhanji Muna
SEC CIK 1846905 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VCYT | VERACYTE, INC. | Dir | 42.7K | — | $509.1K | 11 | 2022-06-16 | 2026-09-01 |
| ARDX | ARDELYX, INC. | Dir | 163.8K | — | — | 3 | 2022-06-15 | 2026-06-16 |
| NTLA | Intellia Therapeutics, Inc. | Dir | 36.4K | — | $95.8K | 11 | 2022-04-28 | 2026-06-09 |
| CYTK | CYTOKINETICS INC | Dir | 26.4K | — | $215.6K | 12 | 2022-01-03 | 2026-05-27 |
Most active insiders at VCYT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Stapley Marc | CEO, Dir | — | $8.92M |
| 2 | JONES EVAN/ FA | Dir | — | $2.00M |
| 3 | Chambers Rebecca | CFO | — | $1.91M |
| 4 | McGuire Annie | SVP, GC | — | $1.80M |
| 5 | Wygant Jonathan | VP, CAO | — | $1.54M |
| 6 | EASTHAM KARIN | Dir | — | $1.49M |
| 7 | Febbo Phillip G. | Chief Scientific, Med Off | — | $1.35M |
| 8 | Leite John | Gbl Chief Commercial Off | — | $1.34M |
| 9 | EPSTEIN ROBERT S | Dir | — | $1.19M |
| 10 | Holstein Jens | Dir | — | $628.3K |
| 11 | Bhanji Muna | Dir | — | $80.1K |
Transactions 37
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-03 16:48 | 2026-09-01 | VCYT | VERACYTE, INC. | Bhanji Muna | Dir | S - Sale | $42.97 | -1,864 | 42.7K | -4% | -$80.1K |
| D | 2026-06-18 16:04 | 2026-06-16 | ARDX | ARDELYX, INC. | Bhanji Muna | Dir | A - Grant | $0.00 | +26.5K | 163.8K | +19% | $0 |
| 2026-06-15 16:55 | 2026-06-11 | VCYT | VERACYTE, INC. | Bhanji Muna | Dir | A - Grant | $0.00 | +5,272 | 44.6K | +13% | $0 | |
| D | 2026-06-10 18:57 | 2026-06-09 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Dir | A - Grant | $0.00 | +9,200 | 36.4K | +34% | $0 |
| D | 2026-05-27 19:16 | 2026-05-27 | CYTK | CYTOKINETICS INC | Bhanji Muna | Dir | A - Grant | $0.00 | +2,851 | 26.4K | +12% | $0 |
| D | 2025-06-23 | 2025-06-18 | ARDX | ARDELYX, INC. | Bhanji Muna | Dir | A - Grant | $0.00 | +41.6K | 137.4K | +43% | $0 |
| 2025-06-23 | 2025-06-18 | VCYT | VERACYTE, INC. | Bhanji Muna | Dir | A - Grant | $0.00 | +9,321 | 39.3K | +31% | $0 | |
| 2025-06-17 | 2025-06-13 | VCYT | VERACYTE, INC. | Bhanji Muna | Dir | S - Sale | $26.67 | -4,589 | 30.0K | -13% | -$122.4K | |
| D | 2025-06-13 | 2025-06-11 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Dir | A - Grant | $0.00 | +8,000 | 27.2K | +42% | $0 |
| 2025-05-15 | 2025-05-15 | CYTK | CYTOKINETICS INC | Bhanji Muna | Dir | S - Sale | $29.73 | -1,454 | 23.5K | -6% | -$43.2K | |
| D | 2025-05-14 | 2025-05-14 | CYTK | CYTOKINETICS INC | Bhanji Muna | Dir | A - Grant | $0.00 | +7,333 | 25.0K | +42% | $0 |
| T | 2025-05-01 | 2025-04-29 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Dir | S - Sale | $8.50 | -265 | 19.2K | -1% | -$2,252 |
| T | 2025-01-31 | 2025-01-29 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Dir | S - Sale | $9.97 | -265 | 19.5K | -1% | -$2,642 |
| 2024-06-17 | 2024-06-13 | VCYT | VERACYTE, INC. | Bhanji Muna | Dir | A - Grant | $0.00 | +11.5K | 34.6K | +50% | $0 | |
| D | 2024-06-14 | 2024-06-12 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Dir | A - Grant | $0.00 | +7,737 | 19.7K | +64% | $0 |
| 2024-06-11 | 2024-06-10 | VCYT | VERACYTE, INC. | Bhanji Muna | Dir | S - Sale | $20.32 | -3,870 | 23.1K | -14% | -$78.6K | |
| 2024-06-10 | 2024-06-10 | CYTK | CYTOKINETICS INC | Bhanji Muna | Dir | S - Sale | $52.07 | -2,000 | 17.6K | -10% | -$104.1K | |
| 2024-05-30 | 2024-05-28 | VCYT | VERACYTE, INC. | Bhanji Muna | Dir | S - Sale | $21.00 | -1,539 | 27.0K | -5% | -$32.3K | |
| D | 2024-05-16 | 2024-05-15 | CYTK | CYTOKINETICS INC | Bhanji Muna | Dir | A - Grant | $0.00 | +5,600 | 19.6K | +40% | $0 |
| 2023-11-02 | 2023-10-31 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Dir | S - Sale | $23.90 | -265 | 12.0K | -2% | -$6,334 | |
| 2023-08-02 | 2023-07-31 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Dir | S - Sale | $42.33 | -265 | 12.3K | -2% | -$11.2K | |
| 2023-07-10 | 2023-07-06 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Dir | S - Sale | $39.30 | -1,867 | 12.5K | -13% | -$73.4K | |
| 2023-07-07 | 2023-07-07 | CYTK | CYTOKINETICS INC | Bhanji Muna | Dir | S - Sale | $34.12 | -2,000 | 14.0K | -12% | -$68.2K | |
| M | 2023-06-21 | 2023-06-16 | VCYT | VERACYTE, INC. | Bhanji Muna | Dir | S - Sale | $26.43 | -5,893 | 28.6K | -17% | -$155.8K |
| D | 2023-06-16 | 2023-06-14 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Dir | A - Grant | $0.00 | +4,425 | 14.4K | +44% | $0 |
| 2023-06-13 | 2023-06-09 | VCYT | VERACYTE, INC. | Bhanji Muna | Dir | A - Grant | $0.00 | +9,674 | 34.4K | +39% | $0 | |
| 2023-06-01 | 2023-05-30 | VCYT | VERACYTE, INC. | Bhanji Muna | Dir | S - Sale | $25.91 | -1,539 | 24.7K | -6% | -$39.9K | |
| D | 2023-05-18 | 2023-05-10 | CYTK | CYTOKINETICS INC | Bhanji Muna | Dir | A - Grant | $0.00 | +5,000 | 16.0K | +45% | $0 |
| 2022-10-05 | 2022-10-03 | CYTK | CYTOKINETICS INC | Bhanji Muna | Dir | A - Grant | $51.11 | +220 | 11.0K | +2% | +$11.2K | |
| 2022-07-12 | 2022-07-01 | CYTK | CYTOKINETICS INC | Bhanji Muna | Dir | A - Grant | $41.00 | +274 | 10.8K | +3% | +$11.2K | |
| D | 2022-06-17 | 2022-06-15 | ARDX | ARDELYX, INC. | Bhanji Muna | Dir | A - Grant | $0.00 | +95.8K | 95.8K | New | $0 |
| 2022-06-16 | 2022-06-16 | VCYT | VERACYTE, INC. | Bhanji Muna | Dir | A - Grant | $0.00 | +14.7K | 26.3K | +128% | $0 | |
| D | 2022-06-16 | 2022-06-14 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Dir | A - Grant | $0.00 | +2,014 | 9,968 | +25% | $0 |
| D | 2022-05-11 | 2022-05-10 | CYTK | CYTOKINETICS INC | Bhanji Muna | Dir | A - Grant | $0.00 | +5,000 | 10.5K | +90% | $0 |
| D | 2022-05-02 | 2022-04-28 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Dir | A - Grant | $0.00 | +7,954 | 7,954 | New | $0 |
| 2022-04-01 | 2022-04-01 | CYTK | CYTOKINETICS INC | Bhanji Muna | Dir | A - Grant | $38.38 | +293 | 5,537 | +6% | +$11.2K | |
| 2022-01-04 | 2022-01-03 | CYTK | CYTOKINETICS INC | Bhanji Muna | Dir | A - Grant | $46.00 | +244 | 5,244 | +5% | +$11.2K |
Purchase Sale Sale after option exercise All abbreviations